Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD [coronary heart disease].

Next Previous
X
Search
Trial Profile

A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD [coronary heart disease].

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rosuvastatin (Primary) ; Ezetimibe; Simvastatin
  • Indications Coronary disorders; Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms GRAVITY
  • Sponsors AstraZeneca

    • Most Recent Events

    • 14 Mar 2010 Results presented at the 59th Annual Scientific Session of the American College of Cardiology.
    • 03 Nov 2008 Status changed from recruiting to completed, based on information from ClinicalTrials.gov.
    • 13 Sep 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top